Glenn Noronha, Ph.d.
Chief Scientific Officer
Chief Scientific Officer
Clearside Biomedical
Russian Federation
Biography
Dr. Noronha was promoted to Chief Scientific Officer in August 2016 after having served as our Executive Vice President, Research and Development since August 2013. Dr. Noronha plays a critical role in all strategic, developmental and regulatory efforts at Clearside. From 2012 to 2013, he served as Vice President, Research and Development, at Sucampo Pharma Americas, LLC. From 2011 to 2012, Dr. Noronha was Chief Scientific Officer for JW Theriac, Inc., a pharmaceutical company focused on new drug research and development in oncology. From 2008 to 2011, Dr. Noronha was Global Project Lead for developmental efforts in retinal diseases at Alcon Laboratories, Inc., a Novartis company. From 2002 to 2008, Dr. Noronha held several positions with increasing levels of leadership and responsibility at TargeGen, Inc., a pharmaceutical company, including as co-lead for its ophthalmology programs. Dr. Noronha received his education and training in Chicago and Irvine
Research Interest
Ophthalmology,Oncology,Pharmaceutical
